CD8A and neoplasm: When ASPIRE was administered, the frequency of PD-1+CD38hi in tumor-infiltrating CD8+ T cells decreased significantly while the frequency of tumor-infiltrating antigen-specific CD8+ T cells showed the opposite trend.